Continuous infusion of DL-α-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 10, 1996, Pages 2318-2320

  Chin, Kevin ^a   Merali, Salim ^a   Sarić, Muhamed ^a   Clarkson Jr , Allen B ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRINKING WATER; EFLORNITHINE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; INFUSION PUMP; INOCULATION; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAT;

EID: 0029820317     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.10.2318     Document Type: Article

References (25)

1. Abeloff, M. D., M. Slavik, G. D. Luk, C. A. Griffin, J. Hermann, O. Blanc, A. Sjoerdsma, and S. Baylin. 1984. Phase I trial and pharmacokinetic studies of α-difluoromethylornithine, an inhibitor of polyamine biosynthesis. J. Clin. Oncol. 2:124-130.
2. Bozzette, S. A., D. M. Finkelstein, S. A. Spector, P. Frame, W. G. Powderly, H. Weili, L. Phillips, D. Craven, C. van der Horst, and J. Feinberg. 1995. A randomized trial of three anti-Pneumacystis agents in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 332:693-699.
3. Clarkson, A. B., Jr., M. Sarić, and R. W. Grady. 1990. Deferoxamine and eflornithine (DL-α-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 34:1833-1835.
4. Clarkson, A. B., Jr., D. E. Williams, and C. Rosenberg. 1988. Efficacy of DL-α-difluorumethylornithine in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 32:1158-1163.
5. Cushion, M. T., D. Stanforth, M. J. Linke, and P. D. Walzer. 1985. Method of testing the susceptibility of Pneumocyslis carinii to antimicrobial agents in vitro. Antimicrob. Agents Chemother. 28:796-801.
6. Gilman, T. M., Y. J. Paulson, J. L. Cohen, P. N. R. Heseltine, and C. T. Boylen. 1987. Multiple-dose pharmacokinetics of eflornithine in AIDS patients treated for Pneumocystis carinii pneumonia, abstr. THP.151. Third International Conference on AIDS.
7. Golden, J. A., A. Sjoerdsma, and D. V. Santi. 1984. Pneumocyslis carinii pneumonia treated with a-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome. West. J. Med. 141:613-623.
8. Grove, J., J. R. Fozard, and P. S. Mamont. 1981. Assay of α-difluoromethylornithine in body fluids and tissues by automatic amino-acid analysis. J. Chromatogr. 223:409-416.
9. Haegele, K. D., R. G. Alken, J. Grove, P. J. Schechter, and J. Koch-Weser. 1981. Kinetics of α-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin. Pharmacol. Ther. 30:210-217.
10. Hughes, W. T., and B. L. Smith. 1984. Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob. Agents Chemother. 26:436-440.
11. Lipschik, G. Y., H. Masur, and J. A. Kovacs. 1991. Polyamine metabolism in Pneumocystis carinii. J. Infect. Dis. 163:1121-1127.
12. Merali, S., K. Chin, R. W. Grady, L. Weissberger, and A. B. Clarkson, Jr. 1995. Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. Antimicrob. Agents Chemother. 39:1442-1444.
13. Merali, S., and A. B. Clarkson, Jr. 1996. Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-α-difluoromethylornithine. Antimicrob. Agents Chemother. 40:973-978.
14. Merrell Dow Pharmaceuticals. 1981. Investigational brochure for DFMO. Merrell Dow Pharmaceutical, Cincinnati, Ohio.
15. Milord, F., L. Loko, L. Éthier, B. Mpia, and J. Pépin. 1993. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. Trans. R. Soc. Trop. Med. Hyg. 87:473-477.
16. Neibart, E. P., F. Dembitzer, G. S. Hammer, R. Dembitzer, H. S. Sacks, and S. Z. Hirschman. 1989. Eflornithine in the treatment of Pneumocyslis carinii pneumonia (PCP), abstr. TBP.29. International Conference on AIDS.
17. Paulson, Y. J., T. M. Gilman, P. N. R. Heseltine, O. P. Sharma, and C. T. Boylen. 1992. Eflornithine treatment of refractory Pneumocyslis carinii pneumonia in patients with acquired immunodeficiency syndrome. Chest 101:66-74.
18. Pesanti, E. L., M. S. Bartlett, and J. W. Smith. 1988. Lack of detectable activity of ornithine decarboxylase in Pneumocystis carinii. J. Infect. Dis. 158:1137-1138.
19. Sahai, J., and A. J. Berry. 1989. Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review. Pharmacotherapy 9:29-33.
20. Sarić, M., and A. B. Clarkson, Jr. 1994. Ornithine decarboxylase in Pneumocystis carinii and implications for therapy. Antimicrob. Agents Chemother. 38:2545-2552.
21. Sattler, F. R., and J. Feinberg. 1992. New developments in the treatment of Pneumocystis carinii pneumonia. Chest 101:451-457.
22. Smith, D., S. Davies, M. Nelson, M. Youle, J. Gleeson, and B. Gazzard. 1990. Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy. AIDS 4:1019-1021.
23. Smith, D. E., S. Davies, J. Smithson, I. Harding, and B. G. Gazzard. 1992. Eflornithine versus cotrimoxizole in the treatment of Pneumocystis carinii pneumonia in AIDS patients. AIDS 6:1489-1493.
24. Vohringer, H.-F., and K. Arasteh. 1993. Pharmacokinetic optimisation in the treatment of Pneunocystis carinii pneumonia. Clin. Pharmacokinet. 24:388-412.
25. Zar, J. 1984. Biostatistical Analysis. 2nd ed. Prentice Hall, Englewood Cliffs, N.J.